Professor Andrew Elefanty is the Group Leader of the Blood Diseases Laboratory at the Murdoch Children’s Research Institute (MCRI). Prof Elefanty's research focuses on the differentiation of human pluripotent stem cells to understand and model blood diseases in vitro and for transplantation. Together with the laboratories of Professor Ed Stanley (Immune Development group) and Dr Elizabeth Ng (Blood Development group) at MCRI, Prof Elefanty has made important contributions to the generation of genetically modified human stem cell lines in which lineage-specific fluorescent reporters allow monitoring of differentiation.
After training as a physician, Professor Elefanty completed a PhD in leukaemogenesis at the Walter and Eliza Hall Institute of Medical Research supervised by Professor Suzanne Cory. He subsequently worked on globin gene regulation with Professor Frank Grosveld at the National Institute for Medical Research in Mill Hill, London before returning to the Hall Institute to pursue interests in developmental haematopoiesis and the differentiation of mouse embryonic stem cells.
He moved to Monash University in 2002 to initiate studies with human embryonic stem cells. In 2013, his laboratory relocated to the Murdoch Children’s Research Institute. In collaboration with Dr Elizabeth Ng and Prof Ed Stanley, he has focused on haematopoietic differentiation of human pluripotent stem cells.
Professor Elefanty holds active collaborations with:
• Professor Ed Stanley, Immune Development Laboratory, Murdoch Children's Research Institute
• Dr Elizabeth Ng, Blood Development Laboratory, Murdoch Children's Research Institute
• Professor Constanze Bonifer, Institute of Cancer and Genomic Sciences, University of Birmingham
• Professor Hanna Mikkola, Department of Molecular, Cell and Developmental Biology University of California
Professor Andrew Elefanty is the Group Leader of the Blood Diseases Laboratory at the Murdoch Children’s Research Institute (MCRI). Prof Elefanty's research focuses on the differentiation of human pluripotent stem cells to understand and model...
Professor Andrew Elefanty is the Group Leader of the Blood Diseases Laboratory at the Murdoch Children’s Research Institute (MCRI). Prof Elefanty's research focuses on the differentiation of human pluripotent stem cells to understand and model blood diseases in vitro and for transplantation. Together with the laboratories of Professor Ed Stanley (Immune Development group) and Dr Elizabeth Ng (Blood Development group) at MCRI, Prof Elefanty has made important contributions to the generation of genetically modified human stem cell lines in which lineage-specific fluorescent reporters allow monitoring of differentiation.
After training as a physician, Professor Elefanty completed a PhD in leukaemogenesis at the Walter and Eliza Hall Institute of Medical Research supervised by Professor Suzanne Cory. He subsequently worked on globin gene regulation with Professor Frank Grosveld at the National Institute for Medical Research in Mill Hill, London before returning to the Hall Institute to pursue interests in developmental haematopoiesis and the differentiation of mouse embryonic stem cells.
He moved to Monash University in 2002 to initiate studies with human embryonic stem cells. In 2013, his laboratory relocated to the Murdoch Children’s Research Institute. In collaboration with Dr Elizabeth Ng and Prof Ed Stanley, he has focused on haematopoietic differentiation of human pluripotent stem cells.
Professor Elefanty holds active collaborations with:
• Professor Ed Stanley, Immune Development Laboratory, Murdoch Children's Research Institute
• Dr Elizabeth Ng, Blood Development Laboratory, Murdoch Children's Research Institute
• Professor Constanze Bonifer, Institute of Cancer and Genomic Sciences, University of Birmingham
• Professor Hanna Mikkola, Department of Molecular, Cell and Developmental Biology University of California
Abberton, K, Tian, P, Elefanty, A, Stanley, E, Leslie, S, Youngson, J, Diviney, M, Holdsworth, R, Tiedemann, K, Little, M, et al.
Banked Cord Blood Is a Potential Source of Cells for Deriving Induced Pluripotent Stem Cell Lines Suitable for Cellular Therapy.
Stem Cells Translational Medicine
7(S1)
:
s13 -s13
2018
view publication
International Stem Cell Initiative.
Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells..
Nat Commun
9(1)
:
1925
2018
view publication
Elwood, N, Abberton, K, Tian, P, Elefanty, A, Stanley, E, Youngson, J, Diviney, M, Holdsworth, R, Tiedemann, K, Little, M.
370 Expanding cellular therapies through provision of A cord blood—derived ipsc haplobank.
Cytotherapy
20(5)
:
e2
2018
view publication
Anderson, DJ, Kaplan, DI, Bell, KM, Koutsis, K, Haynes, JM, Mills, RJ, Phelan, DG, Qian, EL, Leitoguinho, AR, Arasaratnam, D, et al.
NKX2-5 regulates human cardiomyogenesis via a HEY2 dependent transcriptional network..
Nat Commun
9(1)
:
1373
2018
view publication